Excluding the ribosome and riboswitches, developing small molecules that selectively target RNA is a longstanding problem in chemical biology. A typical cellular RNA is difficult to target because it has little tertiary, but abundant secondary structure. We designed allele-selective compounds that target such an RNA, the toxic noncoding repeat expansion (r(CUG)exp) that causes myotonic dystrophy type 1 (DM1). We developed several strategies to generate allele-selective small molecules, including non-covalent binding, covalent binding, cleavage and on-site probe synthesis. Covalent binding and cleavage enabled target profiling in cells derived from individuals with DM1, showing precise recognition of r(CUG)exp. In the on-site probe synthesis approach, small molecules bound adjacent sites in r(CUG)exp and reacted to afford picomolar inhibitors via a proximity-based click reaction only in DM1-affected cells. We expanded this approach to image r(CUG)exp in its natural context.
You may also like
Setting the Brain’s Internal Clock: A Single Neuron...
October 1, 2026Max Planck Florida Institute for Neuroscience
World-Class Research on Schizophrenia
October 1, 2026Max Planck Institute of Psychiatry
Remote-control in the cortex: How distant synapses are...
October 1, 2026Max Planck Institute for Brain Research
Huntington’s Disease: Targeted Light Pulses Improve...
July 30, 2026Max Planck Institute for Biological Intelligence
Perception of Humanness Is Affected by Speech Content
Ribosomes in Pairs: A Survival Strategy Inside...
March 2, 2026Max Planck Institute for Brain Research
